Plus Therapeutics, Inc. Appoints Gregory Stein as Senior Vice President of Clinical Development
April 01, 2020 at 08:00 am
Share
Plus Therapeutics, Inc. announced that Dr. Gregory Stein has joined the Company as Senior Vice President of Clinical Development. Dr. Stein is a highly regarded founder and executive of several healthcare and biotechnology companies. Most recently he co-founded and served as Chief Executive Officer at Curtana Pharmaceuticals. Prior to Curtana, Dr. Stein was also a founder and served as the Vice President, Operations and Medical Affairs at Sova Pharmaceuticals, Inc. In addition, Dr. Stein has held senior positions at Genoptix, Opus Pharmaceuticals and Uzima Bioscience. Dr. Stein was formerly a board-certified Emergency Medicine Physician and previously practiced in Chicago, serving as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
PLUS THERAPEUTICS, INC. 
